PolyPid (NASDAQ:PYPD) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of PolyPid (NASDAQ:PYPD) from a sell rating to a hold rating in a report published on Saturday morning.

PYPD has been the topic of several other reports. Citigroup reaffirmed a “market outperform” rating on shares of PolyPid in a research note on Monday, December 1st. HC Wainwright reissued a “buy” rating and issued a $13.00 price objective on shares of PolyPid in a research report on Wednesday, February 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of PolyPid in a research note on Monday, December 29th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $12.25.

PolyPid Stock Up 5.0%

Shares of NASDAQ:PYPD opened at $4.40 on Friday. The company has a market capitalization of $83.95 million, a P/E ratio of -1.95 and a beta of 1.49. PolyPid has a 52-week low of $2.30 and a 52-week high of $5.12. The stock’s fifty day simple moving average is $4.45 and its 200-day simple moving average is $3.94.

PolyPid (NASDAQ:PYPD) last posted its quarterly earnings data on Wednesday, February 11th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.07). On average, sell-side analysts anticipate that PolyPid will post -1.79 earnings per share for the current year.

Institutional Investors Weigh In On PolyPid

Several large investors have recently made changes to their positions in the business. BNP Paribas Financial Markets raised its stake in shares of PolyPid by 56.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock valued at $32,000 after acquiring an additional 3,500 shares during the period. HighTower Advisors LLC acquired a new position in shares of PolyPid during the 4th quarter valued at $44,000. Jane Street Group LLC purchased a new stake in PolyPid during the 4th quarter worth $66,000. Lumbard & Kellner LLC purchased a new stake in PolyPid during the 2nd quarter worth $135,000. Finally, XTX Topco Ltd increased its holdings in PolyPid by 50.0% in the 4th quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock valued at $142,000 after purchasing an additional 10,888 shares in the last quarter. Institutional investors and hedge funds own 26.47% of the company’s stock.

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.